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Abstract We present health-related quality of life (HRQoL)
data from GADOLIN, comparing bendamustine (B) alone or
combined with obinutuzumab (G-B) in rituximab-refractory
indolent non-Hodgkin lymphoma patients. The Functional
Assessment of Cancer Treatment-Lymphoma (FACT-Lym)
questionnaire was administered on day 1 of cycles 1, 3, and
5 during treatment, at end of induction (EOI), bi-monthly for
2 years during maintenance/follow-up, and annually during
extended follow-up until progression/death. Time to first ≥6-
point worsening from baseline in the FACT-Lym trial outcome
index (TOI) was estimated. Minimally important differences
at individual subscale and total score level were used to define
the proportion of patients reporting improvement on the
FACT-Lym lymphoma-specific subscale (≥3 points), FACT-
Lym TOI (≥6 points), and FACT-Lym total score (≥7 points).
Overall, 396 patients were randomized. Analysis was con-
ducted when 175 Independent Review Committee-assessed
progression-free survival (PFS) events were observed.
Questionnaire completion rates were generally balanced be-
tween arms at baseline, EOI, and final follow-up.Median time
to ≥6-point worsening from baseline on the FACT-Lym TOI
was 8.0 months in the G-B arm and 4.6 months in the B arm
(HR 0.74; 95% CI 0.56–0.98). More G-B patients reported
meaningful improvements on the FACT-Lym questionnaire
subscales. Results were similar when follicular lymphoma pa-
tients were analyzed separately. The delayed time to worsen-
ing and greater proportion of patients reporting meaningful
improvement in HRQoL in the G-B arm suggest that benefit
in PFS is not at the expense of an increase in treatment-related
toxicity that could lead to reduced HRQoL.
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Introduction
Indolent non-Hodgkin lymphoma (iNHL)—including fol-
licular lymphoma (FL) and non-follicular histologies—is
mostly slow growing, but rarely cured. FL accounts for
approximately 70% of iNHL and 22% of all NHL [1].
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Despite significant improvements in response rates and
progression-free survival (PFS) with the addition of ritux-
imab to chemotherapy [2–6], iNHL patients continue to
relapse or become refractory to treatment resulting in lim-
ited treatment options.
Bendamustine (B) has been shown to be effective in
rituximab-refractory (R-refr) patients (75–77% overall
response rate), but median PFS is short [7, 8].
Obinutuzumab (GA101; Gazyva/Gazyvaro; G) is a nov-
el, humanized, glyco-engineered type II anti-CD20
monoclonal antibody, developed to have superior effica-
cy compared with rituximab. In early clinical trials, G
demonstrated encouraging efficacy in relapsed iNHL pa-
tients, and responses were observed in R-refr patients
[9–11]. In the phase III GADOLIN study evaluating B
with or without G in patients with R-refr CD20+ iNHL,
prolonged PFS in the G-B arm was demonstrated [12].
Equally important to improving efficacy outcomes in
these patients is understanding the impact of treatment on
disease- and treatment-related symptoms and function.
Relatively little is known about the health-related quality
of life (HRQoL) of relapsed/refractory (Rel/Refr) and R-
refr iNHL patients. The majority of information comes from
cross-sectional studies of long-term survivors of NHL that
have combined different indolent subtypes and required pa-
tients to be several months from receipt of chemotherapy
[13–15]. In a proportion of these studies, partly because
many iNHL patients are asymptomatic at presentation, the
HRQoL of iNHL patients is akin to that of the general
population. Other studies have highlighted that disease-
related symptoms, such as lymphadenopathy, fatigue, and
disease-related B symptoms (e.g., weight loss, fever, and
night sweats), have a negative impact on patients [14, 15].
A study by Pettengell reported HRQoL in five categories of
FL patients, including one category classified as Bactive dis-
ease-relapsed^ [13]. Although it was a cross-sectional study
and unrelated to specific treatment, this study identified that
patients with active relapsed disease had the lowest scores on
aspects of HRQoL (physical well-being, PWB; functional
well-being, FWB; emotional well-being, EWB; and social/
family well-being, SWB) and lymphoma-related symptoms.
Information on the impact of disease and treatment-related
symptoms on the HRQoL of Rel/Refr and R-refr iNHL pa-
tients, however, is limited.
In evaluating the efficacy benefit of new treatments in
Rel/Refr and R-refr patients, it is important to demon-
strate that any improvement in PFS occurs without ad-
versely impacting HRQoL and that there is an increase
in the time to patient-reported symptom deterioration with
a new treatment. The current study evaluates the impact of
G-B and B on patient-reported HRQoL, lymphoma-
specific symptoms, and health status of patients with R-
refr iNHL in the GADOLIN trial.
Methods
Trial design GADOLIN (NCT01059630) is an open-label,
phase III study of B with or without G in patients with R-
refr CD20+ iNHL. Patients were randomly assigned 1:1 to
the two treatment arms. B patients received 120 mg/m2/day
given intravenously (IV) on days (D) 1 and 2 of each cycle
(C), every 28 days, for up to 6 cycles. G-B patients received
90 mg/m2/day B given IV on D1 and 2 of C1–6. G was ad-
ministered by IV infusion as an absolute dose of 1000 mg on
D1, 8, and 15 of C1 and D1 of C2–6. Patients who did not
progress (complete response, partial response, or stable dis-
ease, at end of induction [EOI] treatment) received G mainte-
nance, 1000 mg IV every 2 months, until progression of dis-
ease (PD) or up to 2 years.
Eligible patients were aged ≥18 years with histologically
documented, R-refr CD20+ iNHL. Patients previously treated
with a maximum of four unique chemotherapy-containing
treatment regimens, with an Eastern Cooperative Oncology
Group (ECOG) performance status of 0, 1, or 2, were includ-
ed. R-refr was defined as no response or progression within
6 months of completion of the last dose of rituximab therapy
(monotherapy or combined with chemotherapy).
GADOLIN was conducted in accordance with the
Declaration of Helsinki and the International Conference on
Harmonization guidelines for Good Clinical Practice. All pa-
tients gave written informed consent. The protocol was ap-
proved by the ethics committees of participating centers and
is registered at ClinicalTrials.gov.
HRQoL assessments The 42-item Functional Assessment of
Cancer Treatment-Lymphoma (FACT-Lym) questionnaire
was used to assess aspects of HRQoL [16, 17]. The FACT-
Lym questionnaire is composed of the FACT-General (FACT-
G)—a 27-item compilation of general questions scored on a 5-
point scale ranging from 0 = Bnot at all^ to 4 = Bvery much^—
and an additional 15 items that assess patient concerns relating
to lymphoma: the FACT-Lym lymphoma-specific subscale
(FACT-Lym LYMS; range, 0–60). FACT-G items are divided
into four primary HRQoL domains: PWB (seven items; range,
0–28), SWB (seven items; range, 0–28), EWB (six items;
range, 0–24), and FWB (seven items; range, 0–28). The
FACT-Lym LYMS consists of common lymphoma disease
and/or treatment-related symptoms (e.g., pain, fever, swelling,
night sweats, insomnia, itching, weight loss, fatigue, and loss
of appetite). Three summary scales: FACT-Lym trial outcome
index (FACT-Lym TOI; range, 0–116; composed of the PWB,
FWB, and FACT-LymLYMS scales); FACT-G (range, 0–108;
composed of the PWB, FWB, SWB, EWB), and the FACT-
Lym total score (FACT-Lym TOT, range, 0–168; composed of
all of the scales) can also be calculated. Higher scores are
reflective of better HRQoL.
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Clinically meaningful minimally important differences
(i.e., the smallest amount of change considered important to
patients) at the individual subscale and FACT-Lym TOT level
were pre-specified and used to define the proportion of pa-
tients reporting meaningful changes on the FACT-Lym LYMS
(≥3 points), FACT-LymTOI (≥6 points), and FACT-LymTOT
(≥7 points) as a result of treatment [18]. The FACT-Lym ques-
tionnaire was administered on D1 of C1, 3, and 5 during
treatment, at EOI, bi-monthly for 2 years (where non-
progressing G-B patients received G maintenance and B pa-
tients were observed), and annually during extended follow-
up until PD.
Statistical methods FACT-Lym questionnaire analysis in-
cluded all randomized patients in the intent-to-treat (ITT) pop-
ulation who had a non-missing baseline and at least one post-
baseline patient-reported outcomes (PRO) assessment.
Subgroup analyses were conducted in the FL subpopulation
based on the stratified randomization for diagnosis. For miss-
ing items within the questionnaire, prorated scores were cal-
culated according to developer guidance [19]. The percentage
of participants randomized to each arm who completed the
FACT-Lym questionnaire at each assessment point after base-
line (PRO completion rates) was calculated and compared.
For each of the FACT-Lym questionnaire scales, descriptive
statistics for recorded values at each visit and changes from
baseline were conducted. In addition to an evaluation of the
overall treatment groups, analyses were conducted to under-
stand if there were differences in patients who reported mean-
ingful changes: the time it took for patients to deteriorate and
the proportion of individuals who improved at each assess-
ment point during the study. Since HRQoL was a secondary
outcome of GADOLIN, and to maintain the pre-specified hi-
erarchical testing structure intended to protect the overall type
I error, hypothesis testing of HRQoL was not conducted.
Results presented herein are considered exploratory in nature.
Survival function of time to earliest occurrence of ≥6-point
worsening from baseline in the FACT-Lym TOI for each arm
was estimated with a Kaplan-Meier curve. If patients did not
have a post-baseline FACT-Lym assessment, data were cen-
sored at the time of randomization: patients who did not reach
≥6-point worsening were censored at their last completed
PRO questionnaire. The proportion of patients who met the
following criteria for FACT-Lym response was summarized
by visit using available data: ≥3-point improvement in the
FACT-Lym LYMS, ≥6-point improvement in the FACT-Lym
TOI, and ≥7-point improvement in the FACT-Lym TOT.
Results
Overall, 396 patients were randomized (194 to G-B and 202 to
B [198 treated]). Baseline characteristics (e.g., proportion of
males/females, ECOG performance scale, iNHL subtype,
Follicular Lymphoma International Prognostic Index score,
time from initial diagnosis to randomization, and presence of
B symptoms) were balanced between arms. Median age was
63 years, and patients had a median of two prior therapies.
Primary study analysis was undertaken when 175
Independent Review Committee (IRC)-assessed PFS events
were observed. PFS was significantly longer with G-B (medi-
an not reached [NR]; 95% confidence interval [CI]
22.5 months—NR) than B (median 14.9 months; 95% CI
12.8–16.6 months); hazard ratio (HR) for progression or death
Fig. 1 Mean change from baseline on FACT-Lym total score—ITT
population. B bendamustine, C cycle, D day, EXT extended, FACT-Lym
Functional Assessment of Cancer Treatment-Lymphoma questionnaire,
FU follow-up, G-B obinutuzumab plus bendamustine, M month, STDY
study, TRTCMP treatment completion, WTH early withdrawal. a For
patients in the G-B arm, follow-up visits occurred during G
maintenance treatment
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was 0.55 (95%CI 0.40–0.74; p = 0.0001). G-B followed by G
maintenance demonstrated manageable toxicity, with a similar
profile to B [12].
Patient-reported HRQoL and disease-related symptoms
FACT-Lym questionnaire completion rates were determined
based on the number of patients who completed the question-
naire divided by the number of evaluable patients. Patients were
evaluable if they were alive at the point the visit was scheduled
and were anticipated to complete study visit assessments, up
until PD or follow-up completion. Completion rates of all scales
were high in the G-B versus B arm during the induction phase
(89.7 vs 88.6% at baseline; 77.7 vs 76.1% at EOI). During the
maintenance/observation follow-up period, the completion rate
in the B arm started to slightly reduce (G-B vs B 75.8 vs 62.8%
at 6 months after EOI; 81.3 vs 67.2% at 12 months after EOI,
and 76.1 vs 58.1% at 18 months after EOI).
Absolute and change from baseline scores: ITT population
Mean and median baseline scores for each of the individual
FACT-Lym questionnaire subscales, and of composite FACT-
G, FACT-Lym TOI, and FACT-Lym TOT, were similar and
well-balanced between arms. For each arm, mean scores were
between 73 and 82% of the total range for each scale, with the
exception of FWB which was the most impaired (64% of the
total range).
Over the course of treatment, there were modest (primarily
<5% of the baseline score) changes in both arms at each as-
sessment in overall mean scores on all FACT-Lym question-
naire scales. The greatest improvements were observed on the
FACT-Lym TOI and FACT-Lym TOT (Fig. 1) for both arms.
In addition, average scores at each assessment were relatively
similar between arms on the FACT-Lym LYMS, FACT-Lym
TOI, and FACT-Lym TOT (Supplementary Table 1), with
some tendency towards higher scores in the G-B arm post
induction.
Time to deterioration: ITT population G-B treatment was
associated with a delay in time to deterioration of FACT-Lym
TOI scores, as defined by a ≥6-point worsening from baseline
[18]. Median time to worsening was 8.0 months in the G-B
arm and 4.6 months in B (Fig. 2a). The Kaplan-Meier estimat-
ed event-free rate for FACT-LymTOI score deterioration (pro-
portion of patients whose composite score had not worsened
by ≥6 points from baseline) was higher in the G-B arm com-
pared with B at 6 months (54.9 vs 44.0%, respectively) and
1 year (46.3 vs 32.1%, respectively), indicating a measure of
clinical benefit for G-B.
The Kaplan-Meier plot of time to deterioration in FACT-
Lym TOI showed that arms started to separate in favor of G-B
at the time of the first scheduled post-baseline PRO assess-
ment on D1 of C3 and remained separated until >18 months
after trial entry when few patients remained at risk.
Importantly, this includes the maintenance phase, where pa-
tients in the G-B arm received G and patients in the B arm
were under observation only.
Clinically meaningful improvement: ITT population
Similarly, a greater proportion of patients reported meaningful
improvement on the FACT-Lym LYMS, FACT-Lym TOI, and
FACT-LymTOT in the G-B arm than B, at various time points
throughout the study (Table 1). By selected treatment-
assessment visits, the greatest difference between arms in
FACT-Lym improvement rates was observed during the initial
2-year maintenance/follow-up period after EOI.
Fig. 2 Kaplan-Meier plots of the FACT-Lym trial outcome index ≥6-
point worsening from baseline in a the ITT population and b the FL
subpopulation. B bendamustine, CI confidence interval, FACT-Lym
Functional Assessment of Cancer Treatment Lymphoma questionnaire,
FL follicular lymphoma, HR hazard ratio, ITT intent-to-treat
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FL subpopulation Most patients (321/396; 81%) in the ITT
population had a FL diagnosis, and it was anticipated that
outcomes in the FL subpopulation would be consistent with
the ITT population. However, since the ITT population in-
cluded non-FL patients with different prognoses than FL pa-
tients, the analyses were repeated for the FL subpopulation
only. As with the ITT population, there were no notable dif-
ferences between treatment arms in any of the average scores
on the FACT-Lym questionnaire subscales at baseline, over
time during the treatment period, and at follow-up.
G-B treatment suggested a longer delay in the time to de-
terioration of FACT-Lym TOI score. Median time to worsen-
ing of FACT-Lym TOI was 7.8 months in the G-B arm and
5.6 months in B (Fig. 2b). Kaplan-Meier estimated event-free
probabilities for FACT-Lym TOI score deterioration were
higher in the G-B arm compared with B at 6 months (52.8
vs 46.7%, respectively) and 1 year (45.0 vs 34.7%, respective-
ly), indicating a degree of clinical benefit for the G-B arm. A
higher proportion of patients in the G-B arm also had im-
provement in their FACT-Lym questionnaire scores during
treatment and follow-up (Table 1).
Discussion
For R-refr iNHL patients, G-B treatment provides an impor-
tant option by achieving an increased PFS over standard of
care with B alone [12]. Of equal importance is understanding
the associated impact on HRQoL.
In GADOLIN, individuals in both treatment arms reported
slightly impaired HRQoL prior to treatment, with the greatest
impairment being observed on the FWB scale whose items in-
clude those focused on ability to work, sleep, and enjoy life and
fun activities. Scores on the PWB, FWB, SWB, and EWB scales
at baseline were roughly 2–3 points lower than the general pop-
ulation averages [20], 1–3 points lower than scores reported by a
disease-free NHL (all subtypes) sample [21], but 0–7 points
higher than a group of active disease-relapsed FL patients [13].
This observation suggests that patients experienced a clinically
meaningful lower HRQoL as compared to the general popula-
tion, but higher HRQoL than published data on patients with
relapsed disease. As 15/34 (44%) of the active disease-relapsed
patients in the Pettengell study were receiving chemotherapy at
the time of assessment, it is possible that the difference observed
is the result of the unspecified chemotherapy regimen received
by patients adversely impacting their HRQoL [13].
During the study, there was minimal change in the overall
group average scale scores in both arms. Theseminimal changes
from baseline are consistent with the lack of a significant decline
in FACT-Lym TOT, FACT-Lym questionnaire, or the European
Organization for Research and Treatment of Cancer QLQ-C30
subscale scores during the study period reported in frontline and
previously treated rituximab-exposed iNHL patients [22, 23].
While no clear improvement in HRQoL was observed with G-
B treatment, when looking at the overall sample, results showed
no evidence to suggest that G-B treatment reduced patient-
reported HRQoL—an important factor in refractory iNHL pa-
tients in need of alternative treatment.
Table 1 Summary of meaningful improvement in FACT-Lym (ITT population and FL subpopulation)a
FACT-Lym questionnaire subscale
(definition of meaningful improvement)b
ITT FL
B (n = 202) G-B (n = 194) B (n = 166) G-B (n = 155)
FACT-Lym LYMS (≥3-point increase)
C5 and D1 (induction treatment) (%) 44/142 (31.0) 61/148 (41.2) 39/115 (33.9) 47/117 (40.2)
Follow-up visit 4 and 6 months post-EOI (%) 29/76 (38.2) 48/99 (48.5) 23/57 (40.4) 35/78 (44.9)
Follow-up visit 8 and 12 months post-EOI (%) 17/44 (38.6) 37/77 (48.1) 15/32 (46.9) 29/61 (47.5)
FACT-Lym TOI (≥6-point increase)
C5 and D1 (induction treatment) (%) 32/143 (22.4) 52/149 (34.9) 28/115 (24.3) 40/118 (33.9)
Follow-up visit 4 and 6 months post-EOI (%) 22/77 (28.6) 43/99 (43.4) 17/58 (29.3) 32/78 (41.0)
Follow-up visit 8 and 12 months post-EOI (%) 12/44 (27.3) 37/77 (48.1) 10/32 (31.3) 28/61 (45.9)
FACT-Lym TOT (≥7-point increase)
C5 and D1 (induction treatment) (%) 33/143 (23.1) 41/149 (27.5) 29/115 (25.2) 30/118 (25.4)
Follow-up visit 4 and 6 months post-EOI (%) 26/77 (33.8) 42/99 (42.4) 20/58 (34.5) 32/78 (41.0)
Follow-up visit 8 and 12 months post-EOI (%) 13/44 (29.5) 35/77 (45.5) 10/32 (31.3) 26/61 (42.6)
B bendamustine, C cycle, D day, EOI end of induction, FACT-Lym Functional Assessment of Cancer Treatment-Lymphoma questionnaire, FACT-Lym
LYMS FACT-Lym lymphoma-specific subscale, FACT-Lym TOI FACT-Lym trial outcome index, FACT-Lym TOT FACT-Lym total score, FL follicular
lymphoma, G-B obinutuzumab plus bendamustine, ITT intent-to-treat
a Values are n/total n (%); scale score increases of ≥3, ≥6, and ≥7 points are reflective of the amounts of change that represent a clinically meaningful
improvement in patient HRQoL
b For patients in the G-B arm, follow-up assessments occurred during G maintenance treatment
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Although there were no differences between arms in the
overall sample average scores, there were differences in patients
who reported clinically meaningful changes over the course of
the study: a longer time to clinically meaningful deterioration in
lymphoma-related HRQoL in the G-B arm compared with B
alone. In addition, G-B followed by Gmaintenance resulted in a
greater proportion of patients reporting a meaningful improve-
ment in HRQoL throughout the study. This improvement oc-
curred in the G-B arm even during induction, despite similar
clinical response rates [12], and the benefit was sustained over
time despite the delivery of additional G treatment.
In the primary GADOLIN manuscript, subgroup analyses
of efficacy demonstrated that the benefit of G-B was seen in
the majority of subgroups tested, including FL (81% of ITT),
in whom the stratified HR for IRC-assessed PFS in the G-B
arm relative to B alone was 0.48 (95% CI 0.34–0.68) [12]. It
was important to determine whether the clinical benefit ob-
served in FL patients was consistent for HRQoL, which would
provide additional support for the benefit of G-B treatment. As
noted, results of HRQoL analysis were similar between the
overall ITT population and FL subpopulation.
The primary limitation of this study is the decreased num-
ber of patients completing the HRQoL questionnaires over
time. Although completion rates in the B arm started to re-
duce, the degree of missing data among those who were pro-
gression free and evaluable to complete the questionnaires
was not markedly different between treatment arms.
Therefore, it is likely that the scores are a reflection of the
HRQoL of treated patients. At 18 months from EOI, 75
evaluable patients remained in the G-B arm and 25 in B.
This was due to a combination of PD, death, study discontin-
uation, and the study being reported after reaching statistically
significant results in PFS at interim analysis. If completion
rates are examined based on the proportion of FACT-Lym
questionnaire data missing, due to attrition and non-compli-
ance, the difference between arms is more pronounced than
due to compliance alone. Specifically, the proportion of data
missing was higher in the B arm during follow-up/mainte-
nance (61% in B arm at 6 months after EOI; 76% at 12months
after EOI; 81% at 18 months after EOI) than the correspond-
ing numbers for G-B (41, 52, 57%, respectively), which is in
line with the higher attrition rates due to PD and death in the B
arm. A further limitation is that after PD, HRQoL question-
naires were only collected at study treatment/follow-up termi-
nation visit, and <50% of patients with PD completed them,
which could potentially have biased the results. The propor-
tion of patients that were event free with respect to progression
or death in the G-B versus B arm was 76.6 versus 57.4% after
1 year and 59.4 versus 35.4% after 1.5 years from randomi-
zation. If we consider progression to have an adverse impact
on HRQoL data, then data reported only from the non-
progressed patients are likely an overestimate of the true
HRQoL. As the progression rate was significantly greater in
the B arm (and thus the relapse-free follow-up shorter), this
could be interpreted as the change from baseline in HRQoL is
biased upwards to a greater extent in the B arm compared with
G-B.
As the aim of treatment for R-refr iNHL patients is to max-
imize PFS, maintain HRQoL, and minimize treatment-related
morbidity, the results of GADOLIN highlight the benefit that
G-B treatment confers over B alone in some patients, while
maintaining pre-treatment levels of HRQoL. There was no
evidence to suggest that G-B treatment reduced patient-
reported HRQoL, and in a proportion of patients, resulted in
meaningful improvements in lymphoma-related symptoms.
Our results suggest that improved PFS is not at the expense
of an increase in treatment-related toxicity that could lead to a
reduction in a patient’s HRQoL.
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